3 buy-rated ASX 200 shares that analysts love

If you’re interested in adding some ASX 200 shares to your portfolio this week, then the three listed below could be worth considering.

These ASX 200 shares have all been named as buys recently. Here’s what you need to know about them:

Cochlear Limited (ASX: COH)

The first ASX 200 share to look at is Cochlear. It is one of the world’s leading hearing solutions companies with a portfolio of industry-leading cochlear implant devices.

Goldman Sachs is a fan of Cochlear. In response to its recent full year results, the broker reiterated its buy rating with an improved price target of $247.00. Goldman believes that Cochlear will grow its net profit by “a +10% CAGR from FY22-25E.”

Goodman Group (ASX: GMG)

Another ASX 200 share that could be a top option for investors is Goodman Group. It is one of the world’s leading integrated commercial and industrial property companies.

Goodman has been growing at a strong rate for years thanks to its expertly constructed portfolio that gives it exposure to key growth markets such as ecommerce and logistics.

The team at Citi is bullish on Goodman and expects its strong growth to continue. The broker recently commented: “We revise medium-term earnings higher and see upside to FY23 guidance of 90.3c (11% EPS growth) driven by (1) another strong year of development earnings growth, (2) continued rise in management and investment income driven by high asset values and recent development completions.”

Citi has a buy rating and $23.50 price target on the company’s shares.

ResMed Inc. (ASX: RMD)

A final ASX 200 share to look at is ResMed. It is another industry leader, this time in the sleep treatment market.

Like the others, the company has been growing at a strong rate for years and has been tipped to continue doing so for the foreseeable future.

Morgans is a fan of ResMed. It believes there is “a multi-year opportunity for RMD to growth at or above market and solidify its market leadership position.” The broker has an add rating and $37.08 price target on its shares.

The post 3 buy-rated ASX 200 shares that analysts love appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Goldman Sachs tips Cochlear share price to rise 13%
• 5 things to watch on the ASX 200 on Monday
• Why Accent, Cochlear, Newcrest, and Santos shares are charging higher today
• Cochlear share price takes off despite guidance miss
• Cochlear share price in focus as sales revenue surges to record $1.6b

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/MJvH9Cd